PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases

Journal of Cancer

Volumn 5, Issue 3, 2014, Pages 166-172

  Jilaveanu, L B ^a   Shuch, Brain ^a   Zito, C R ^a,b   Parisi, F ^a   Barr, M ^a   Kluger, Y ^a   Chen, L ^a   Kluger, H M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SAINT JOSEPH   (United States)

Author keywords

PD L1; Renal cell carcinoma

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; MIDDLE AGED; NEPHRECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR BIOPSY; TUMOR ESCAPE; TUMOR VOLUME; YOUNG ADULT;

EID: 84896974949     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8167     Document Type: Article

References (36)

1. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J Urol. 1977; 118: 538-42.
2. deKernion JB, Sarna G, Figlin R, Lindner A, Smith RB. The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol. 1983; 130: 1063-6.
3. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313: 1485-92. doi:10.1056/NEJM198512053132327.
4. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271: 907-13.
5. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998; 83: 797-805.
6. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008; 113: 293-301. doi:10.1002/cncr.23552.
7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994; 7: 85-90.
8. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399: 271-5.
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427-34. doi:10.1056/NEJMoa021491. 349/5/427 [pii].
10. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003; 9: 1648-55.
11. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30: 482-7. doi:10.1200/JCO.2011.37.2516.
12. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271: 1734-6.
13. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30: 825-30. doi:10.1097/CJI.0b013e318156e47e.
14. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor- associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800. doi:10.1038/nm730.
15. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101: 17174-9. doi:0406351101 [pii]. 10.1073/pnas.0406351101.
16. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005; 104: 2084-91. doi:10.1002/cncr.21470.
17. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99: 12293-7. doi:10.1073/pnas.192461099.
18. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-54. doi:10.1056/NEJMoa1200690.
19. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013; 31(suppl): abstr3000.
20. Powderly JD, Koeppen H, Hodi FS, Sosman JA, Gettinger SN, Desai R, et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol. 2013; 31(suppl): abstr3001.
21. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66: 3381-5. doi:66/7/3381 [pii]. 10.1158/0008-5472.CAN-05-4303.
22. Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, et al. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol. 2013; 13: 3. doi:10.1186/1472-6890-13-3.
23. Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med. 2013; 11: 15. doi:10.1186/1479-5876-11-15.
24. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8: 1323-7. doi:10.1038/nm791.
25. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra37. doi:4/127/127ra37 [pii] 10.1126/scitranslmed.3003689.
26. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012; 13: 927-35. doi:10.1016/S1470-2045(12)70285-1.
27. Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012; 23 Suppl 8: viii35-40. doi:10.1093/annonc/mds261.
28. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-44. doi:10.1056/NEJMoa1305133.
29. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-65. doi:10.1056/NEJMoa1200694.
30. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9: 802-11.
31. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5: 379-85.
32. Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, et al. Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma. Frontiers in oncology. 2012; 2: 51. doi:10.3389/fonc.2012.00051.
33. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012; 366: 883-92. doi:10.1056/NEJMoa1113205.
34. Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, et al. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol. 2013; 13: 3. doi:10.1186/1472-6890-13-3.
35. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80: 1943-9.
36. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167-75. doi:JCO.2009.26.7609 [pii]